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BY-NC-ND license (http://creativecomBackground: Asthma is a common allergic disease. In previous studies, probiotics improved the
balance of intestinal microbes, reduced inflammation, and promoted mucosal tolerance. This
study investigated whether oral administrations of Lactobacillus rhamnosus GG (LGG) inhibited
allergen (ovalbumin or OVA)-induced airway inflammation in a mouse asthma model.
Methods: The allergy/asthma animal model in this study was sensitization with OVA. After
intranasal challenge with OVA, the airway inflammation and hyper-responsiveness were deter-
mined by a Buxco system, bronchoalveolar lavage fluid analysis with Liu stain, and enzyme-
linked immunosorbent assay. Histopathologic changes in the lung were detected by hematox-
ylin and eosin staining and immunohistochemistry staining.
Results: Both pre- and post-treatment with LGG suppressed the airway hyper-responsiveness
to methacholine and significantly decreased the number of infiltrating inflammatory cells
and Th2 cytokines in bronchoalveolar lavage fluid and serum compared with the
OVA-sensitized mice. In addition, LGG reduced OVA-specific IgE levels in serum. Oral LGG
decreased matrix metalloproteinase 9 expression in lung tissue and inhibited inflammatory cell
infiltration.llergy, Asthma and Rheumatology, Department of Pediatrics, Chung Shan Medical University Hospital,
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.tw, kohuang.lue@gmail.com (K.-H. Lue).
ors.
.08.001
ociety of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC
mons.org/licenses/by-nc-nd/4.0/).
626 C.-T. Wu et al.Conclusion: LGG had an anti-inflammatory effect on OVA-induced airway inflammation and
might be an additional or supplementary therapy for allergic airway diseases.
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The past 3 decades have seen an increase in the prevalence of
asthma, eczema, and allergic rhinitis in developed countries.
A number of environmental factors including air pollution,
cigarette smoking, and allergen exposure have been pro-
posed to explain the changes in the prevalence of asthma.1,2
In Taiwan, asthma, bronchitis, emphysema, and coronary
obstructive pulmonary disease are ranked seventh among the
leading causes of death.3,4 The inhalation of allergens stim-
ulates bothbonemarrow-derived cells and non-bonemarrow-
derived cells in the innate immune system to secrete cyto-
kines that promote antigen expressions on CD4þ T cells, and
activate the antigen presenting cells and the T cells to pro-
duce Th2 responses.5,6 Th2 cytokines, such us interleukin
(IL)-4, IL-5, IL-9, and IL-13, then induce the changes in the
airways and lung parenchyma that are associated with
asthma, airway eosinophilia, pulmonary lymphocytosis,
mastocytosis, alternative macrophage activation, and
epithelial cell proliferation with goblet cell hyperplasia.5
Moreover, increased Th2 cytokines lead to mucus secretion,
smooth muscle hyperplasia, hypertrophy, hypercontractility,
subepithelial fibrosis, immunoglobulin E (IgE) secretion,
increased production of con chemokines that attract T cells,
eosinophils, neutrophils, mast cells, and airway hyper-
responsiveness (AHR).5 Hyper-responsiveness is defined as
an increased sensitivity to agents, such as cholinergic agents
and other stimuli that cause smooth muscle contractions and
increased airway resistance by narrowing the airways.7e9
Previous studies have also shown that matrix metal-
loproteinases (MMPs) are members of a family of enzymes
that cleave extracellular matrix proteins. Furthermore,
MMPs have been implicated in many inflammatory condi-
tions.10 Specifically, in asthma patients MMP9 levels in-
crease significantly.11 MMP9 may therefore be the dominant
MMP in the airways of asthmatics. This suggests that MMP9
plays an important role in monitoring treatment response
and airway remodeling in asthma, but the role of MMPs in
asthma and inflammation diseases remains unclear. In this
study, we investigated the expression of MMP9 in bron-
choalveolar lavage fluid (BALF) and serum before and after
Lactobacillus rhamnosus GG (LGG) treatment.
An inhaled corticosteroid is the principle treatment for
asthma. However, this therapy is not applicable for a
considerable percentage of patients with asthma, and only
about one third of patients actually benefit from the
addition of leukotriene inhibitors.12,13 Severe and
corticosteroid-resistant forms of asthma actually lead to
life-threatening attacks, and the mortality rate of this
disease is showing an increasing trend.14 There is thus an
urgent need to devise treatments for asthma that are more
effective. Due to the involvement of cytokines in chronicinflammation and airway remodeling,13,14 they are the main
targets in novel allergy and asthma therapies.
The Food and Agriculture Organization of the United Na-
tions defines probiotics as “Live microorganisms that when
administered in adequate amounts confer a health benefit on
the host”.15,16 In other words, ingested probiotics could
modify microbial populations to benefit the host. Previous
studies have shown that probiotics can reduce allergic dis-
eases by modifying the immune system of the host.17 More-
over, several studies have reported that oral Lactobacillus
strains have beneficial effects on perennial allergic rhinitis
and pollen allergies,18e22 but the mechanisms underlying the
effects on the immune system are unclear.
Previous studies23e25 have reported that administration of
microbial supplements such as probiotic bacteria during
pregnancyorearly lifemightprevent allergy-relateddiseases.
However, unlike previous studies, our study focused on
whether the effect of treatment with oral probiotics on
adults is the same as prevention. Based on this idea, we
used 6- to 8-week-old adult mice. The groupings of LGG-
treated mice included the prevention group (pre-LGG, oral
LGG on Days 1e14 during sensitized experimental process)
and the treatment group (post-LGG, oral LGG on Days
14e27 during a sensitized experimental process) to analyze
the effects of LGG on allergic diseases at different times. If
oral probiotics can cause an improvement in adult allergy
patients, it will be good news.
We used the probiotic bacterium LGG because in a
previous study by our team26 the administration of LGG
decreased symptoms in patients with allergic rhinitis.
Moreover, some studies27,28 have also shown that Lactoba-
cillus probiotic can modulate the Th1/Th2 immune
response, and it has been reported that LGG administered
postnatally can reduce the risk of allergic diseases.28
Asthma/allergies can, however, be caused by a Th1/Th2
imbalance, and in order to advance previous research we
chose LGG in this allergy/asthma study. In the current
study, we hypothesized that orally-administrated LGG will
induce and affect the balance of the Th1/Th2 response. To
test this hypothesis, oral LGG treatment during the OVA-
sensitization/challenge was evaluated for the effect of LGG
in pre-established Th2 responsive mice. Moreover, in this
study we also detected MMP9 expression in BALF and serum
to analyze the effect of MMP9 on treatment with oral LGG.Materials and methods
Mice
Female BALB/c mice at 5e8 weeks of age with body weights
of 20e25 g were purchased from the National Laboratory
Oral LGG could decrease airway inflammation 627Animal Center (Taipei, Taiwan). All animal care and housing
requirements and all procedures were performed in
accordance with the Chung Shan Medical University Insti-
tutional Animal Care and Use Committee (Animal Experi-
ment Approval code: 1185), Taichung, Taiwan. Animals
known to be high IgE responders were used, and the mice
were maintained on an ovalbumin (OVA)-free diet and were
individually housed in rack-mounted stainless steel cages
with free access to food and water. The mice were divided
into four experimental groups. The four groups of mice
were treated as follows: (1) the normal control group
received normal saline plus alum intraperitoneally and
normal saline intranasally; (2) the positive group received
50 mg OVA plus alum intraperitoneally and 5% OVA intra-
nasally; and (3) the pre- and (4) post-LGG groups received
50 mg OVA plus alum intraperitoneally and 5% OVA intra-
nasally, and were fed 0.018 mg/pc/day of LGG.
The pre-treatment group (pre-LGG) received LGG from
Day 1 to Day 14 as a method of prevention. The post-
treatment group (post-LGG) received LGG from Day 14 to
Day 27 as a method of treatment.
The probiotic
The LGG powder (TTY Biopharm Company Limited, Taipei,
Taiwan) was stored at 20C. Drinks were prepared using
double distilled H20 (ddH20) only and ddH2O plus LGG.
Eighteen micrograms of LGG powder were dissolved in
10 mL ddH2O.
The mouse model of allergic asthma
The allergic asthma model is as shown in Fig. 1A. The mice
received normal saline with alum or were sensitized to OVA
intraperitoneally with alum (50 mg OVA in alum) on Day 1,
Day 2, Day 3 and Day 14, followed by intranasal OVA chal-
lenges (5% solution, 50 mL) or normal saline on Day 14, Day
17, Day 21, Day 24, and Day 27. The animals received either
the control vehicle or LGG feeding (0.018 mg/pc/day LGG
diluted in ddH2O) from Day 1 to Day 14 (pre-LGG mice, as
shown in Fig. 1B), or from Day 14 to Day 27 (post-LGG mice,Figure 1. The protocols used for the mouse models of allergic as
asthma. (B) The protocols used for the mouse models of allergic asth
(C) The protocols used for themousemodels of allergic asthma and p
pc/day of LGG. Ovalbumin (OVA)-sensitized mice were given 50 mg/as shown in Fig. 1C). The normal control group consisted of
five mice; the positive control had nine mice; and the pre-
and post-treatment LGG groups (pre-LGG, pre; post-LGG,
post) each had seven mice.
In this study, we performed independent experiments
more than three times. We therefore confirmed that this is
a successful animal model of allergic asthma, so we used
this animal model in our asthma and allergic disease study.
AHR and bronchoalveolar lavage fluid isolation
AHR was assessed in unrestrained mice through whole-body
barometric plethysmography (Model PLY 3211; Buxco Elec-
tronic Inc., Sharon, CT, USA) to record the enhanced pause
(Penh). Penh, a dimensionless parameter, was used to
measure the pulmonary resistance, which was calculated
by changing the chamber pressures through methacholine
challenge during inspiration and expiration. After a brief
acclimatization to the chamber, the mice received an
initial baseline challenge of saline, followed by increasing
doses of nebulized methacholine. During the exposure
period, each mouse was given 0 mg/mL (saline), 5 mg/mL,
10 mg/mL, or 20 mg/mL methacholine. Mice remained in
the chamber for 3 minutes. The respiratory rate was
counted during the 3-minute methacholine challenge. After
that, the Penh values were averaged and reported as
baseline saline values in percentages.29,30
BALF was isolated in 1 mL of phosphate buffered saline.
The BALF cellularity was determined using a hemocytom-
eter. The cells were centrifuged (4000  rpm, 5 min),
transferred onto slides, and were fixed and stained using
Liu stain. The observer counted 200e300 cells per slide
using the standard morphological criteria to classify the
individual leukocyte populations.31,32
The measurement of OVA-specific antibodies in
serum
The serum levels of OVA-specific IgE and IgG2a were deter-
mined first. In short, the 96-well microtitre plates were
coated with 100 mg/mL of OVA in 0.1M NaHCO3 at 4C andthma. (A) The protocols used for the mouse models of allergic
ma and pre-treatment with Lactobacillus rhamnosus GG (LGG).
ost-treatment with LGG. In (B) and (C), mice were fed 0.018mg/
pc I.P. (intraperitoneal) and 5% OVA solution I.N. (intranasal).
Figure 2. The effects of Lactobacillus rhamnosus GG (LGG)
on the pre- and post-treatment mouse models of allergic
asthma. The female bronchoalveolar lavage fluid (BALB)/c mice
were given normal saline (normal control group) or were sensi-
tized/challenged with ovalbumin (OVA)  treatment with LGG.
The airway hyper-responsiveness to methacholine was assessed
in a Buxco system to record the enhanced pause (Penh). The
Penh value in the positive control (PC,-) group was higher than
the other groups. However, the Penh value in the oral pre- and
post-LGG groups (:,) was significantly decreased. The normal
control (NC, A) group was lower than all of the groups. NC,
nZ 5 for the NC group; PC, nZ 9 for OVA only treatment group;
pre-LGG, nZ 7 for pre-treatment LGG; and post-LGG, nZ 7 for
post-treatment LGG. The statistical analysis compared OVA-
treated mice and is represented as: *p < 0.05, **p < 0.01, and
***p < 0.001. Airway hyperresponsiveness (AHR).
628 C.-T. Wu et al.left overnight. The plates were washed with Tween 20 so-
lution (0.05%) and then blocked with bovine serum albumin
(3%) for 1 hour at 37C. After washing, 50 mL of serially
diluted sera in 3% bovine serum albumin was added and
incubated at 4C and the plates were left unattended over-
night. After washing, horseradish peroxidase conjugated
with anti-mouse isotype-specific antibody (BD Pharmingen,
San Jose, CA, USA) and optimal dilutions were added. The
plates were incubated at 37C for 2 hours and were then
washed. To determine the IgE/IgG2a, p-nitrophenyl phos-
phate substrate (Sigma Chemical Co., St Louis, MO, USA) was
added and the absorbance at 490 nm was measured. The
detection antibody was alkaline phosphatase-labeled.
The measurement of cytokines
Serum and BALF samples were collected from each group of
mice after the mice were sacrificed. The samples were
assayed for the presence of cytokines using the R&D system
(Boston, MA, USA) following the manufacturer’s protocol.
After that, interferon-gamma (IFN-g, limit of detection:
9.5 pg/mL), IL-4 (limit of detection: 8.0 pg/mL), IL-5 (limit
of detection: 16.1 pg/mL), IL-10 (limit of detection:
15.9 pg/mL), IL-12p70 (limit of detection: 8.3 pg/mL), IL-13
(limit of detection: 41 pg/mL), and transforming growth
factor beta (TGF-b, limit of detection: 31.2 pg/mL) levels
were assayed according to the manufacturer’s protocol
(Quantikine ELISA Kit, R&D Systems, Boston, MA, USA), and
the enzyme-linked immunosorbent assay (ELISA) plate was
read at 450 nm using a Bio-Rad ELISA Reader (Bio-Rad,
Hercules, CA, USA). The data were then analyzed using
SoftMax Pro software (Molecular Devices, Sunnyvale, CA,
USA). The unknowns were compared using a standard curve
containing at least five to seven dilution points, which were
the relevant recombinant cytokines on each assay plate.
The measurement of MMP9
The serum and BALF samples were collected from each
group of mice after the mice were sacrificed. The R&D
Systems Quantikine ELISA Kit was used to analyze the
samples. However, MMP9 levels (limit of detection:
31.3 pg/mL) were assayed according to the manufacturer’s
protocol, and the ELISA plate was read at 450 nm using a
Bio-Rad ELISA Reader. The data were then analyzed using
SoftMax Pro software (Molecular Devices). The unknowns
were compared using a standard curve containing at least
five to seven dilution points, which were the relevant re-
combinant cytokines on each assay plate.
Histological analysis
To assess the pathological changes, samples of the lungs
were taken after the mice were sacrificed. The samples
were fixed in neutrally buffered 10% formaldehyde and
were embedded in paraffin. Five-micrometer sections were
stained with hematoxylin and eosin to detect inflammatory
cell infiltration in the lung tissue. The figure for airway
inflammation was detected by hematoxylin and eosin
staining with a magnification ratio of 1:200.Statistical analysis
All data points represent the mean  standard error of the
mean of the individual mouse groups. Analysis was per-
formed using GraphPad Instat software (San Diego, CA,
USA), and the Mann-Whitney nonparametric test was con-
ducted to determine the statistical significance, where
appropriate. A p-value of < 0.05 was considered significant.
Results
The effect of LGG on the AHR
The Buxco system was applied to detect lung function. We
also wanted to analyze whether administrated LGG would
suppress AHR in sensitized mice. The OVA-sensitized and
challenged mice were significantly more sensitive to
methacholine exposure than the normal control group
(Penh value: 10.37  4.2 vs. 0.27  0.13, respectively;
p < 0.007). In this study, we investigated whether LGG had
a beneficial effect on inflammation. The mice that received
LGG during Days 1e14 as a means of prevention (pre-LGG,
Penh value: 4.02  2.9), had significantly lower AHR to
methacholine compared with the OVA mice tested at the
20 mg/mL level (p < 0.0012) and comparable responses in
the normal control animals were observed at the same
dose. Similar results were observed in terms of significant
inhibition of AHR when LGG was administered during Days
14e27 as a means of treatment (post-LGG; Penh value:
4.32  3.3; Fig. 2).
Oral LGG could decrease airway inflammation 629The effect of LGG treatment on the reversal of
allergen-induced serum OVA-specific antibodies in
serum
Herein, we detected whether oral LGG would decrease
serum levels of IgE, and increase the Th1 response by
measuring IgG2a. ELISA was used for data analysis. The
serum levels of OVA-specific IgE and IgG2a were signifi-
cantly elevated after the OVA sensitization/challenge
compared with the normal control group. In the group that
received oral LGG treatment (pre- and post-treatment)
during the OVA sensitization/challenge, the serum IgE was
significantly decreased (p < 0.05, Fig. 3A). Moreover, the
serum IgG2a was also significantly increased (p < 0.005,
Fig. 3B).
The effect of LGG on the infiltrating cells of the
lungs
Previous studies have reported that cell infiltration of the
lung is a hallmark of asthma. In order to analyze the infil-
tration of cells into the lung, we used cytospin and Liu stain
to evaluate BALF. Differential cell counts (Fig. 4) revealed
that total cells, eosinophils, lymphocytes and monocytes
were significantly increased in the OVA-sensitized mice
compared to the control group. However, the infiltrating
cells of the lung were significantly decreased in the two
groups treated with LGG (p < 0.05).
The effect of LGG treatment on cytokines in serum
and BALF
Th1 and Th2 system imbalance is characteristic of asth-
ma/allergic diseases. In this study, we tested the Th1 and
Th2 cytokines after LGG treatment to determine whether
oral LGG would decrease Th2 cytokine secretion and in-
crease Th1 cytokine.
Th2 cytokines in the OVA-sensitized/challenged mice
were increased compared with the normal control group.
IFN-g was significantly decreased in the OVA-sensitizedFigure 3. The effects of Lactobacillus rhamnosus GG (LGG) trea
serum levels in the ovalbumin (OVA)-treated mice. Serum OVA-sp
normal control group and the OVA sensitized/challenged mice (posi
significant expression of OVA-specific IgE in the positive control grou
expression. (B) OVA-specific IgG2a expression in serum; the groups t
compared OVA-treated mice and is represented as: *p < 0.05; **pgroup. Besides this, not only Th1 cytokines but also regu-
latory T (Treg) cytokines including IL-12, IFN-g and TGF-b
were significantly increased in the LGG pre- and post-
treatment groups (Fig. 5). Moreover, the LGG treatment
administered during the challenge phase significantly
decreased the Th2 cytokines, including IL-4, IL-5, and IL-13.
However, IL-10 was significantly decreased in the serum and
BALF after LGG treatment (Fig. 6).
The effect of LGG on lung inflammation
Next, we assessed the inflammation of lung tissue. One of
the hallmarks of asthma is lung inflammation, so we
analyzed by histology whether LGG would improve lung
inflammation.
The effect of LGG treatment on the OVA-sensitized/
challenged mice on overall lung inflammation was evalu-
ated through histological hematoxylin and eosin staining
(Fig. 7). The normal control group (Fig. 7A) and the mice in
the OVA-sensitized/challenged (Fig. 7B) group (positive
control) with allergic asthma had severe inflammation; in
the pre- and post-treatment LGG models (Fig. 7 C and D) of
allergic asthma after LGG treatment, there was signifi-
cantly less inflammation. A morphometric examination of
the airway sections revealed that the OVA exposure
(Fig. 7B) significantly increased the epithelial cell thick-
ness. In both groups (Fig. 7C and D) treated with LGG, there
was a decrease in epithelial cell thickness compared to the
OVA mice.
The effect of LGG on MMP9 expression
The MMP9 expression was highly associated with inflam-
mation, asthma, and airway remodeling. We therefore
detected the MMP9 levels in serum and BALF to analyze the
MMP9 concentration after LGG treatment.
The effect of the LGG treatment in the OVA-sensitized/
challenged mice on the MMP9 expression in serum and BALF
was detected using ELISA (Table 1). The mice that were
OVA-sensitized/challenged in the allergic asthma models
had stronger expression of MMP9 compared with the normaltment on the specific anti-OVA immunoglobulin (Ig)E and IgG2a
ecific IgE and IgG2a concentrations were obtained from the
tive control) or presence of treatment with LGG. (A) There was
p, and groups with pre- and post-treatment LGG had decreased
reated with LGG increased significantly. The statistical analysis
< 0.01, and ***p < 0.001.
Figure 4. The effects of the Lactobacillus rhamnosus GG (LGG) treatment on the inflammatory cell infiltrations in bron-
choalveolar lavage fluid (BALF) of ovalbumin (OVA)-treated mice. All cell counts were obtained from the normal control group and
OVA sensitized/challenged mice (positive control, PC) or presence of treatment with LGG. The total cells and inflammatory cells
were counted (104) in BALF in millimeters by the morphometric evaluations of cytospin preparations. (A) Total cell count in BALF.
A large number of cells was expressed in BALF of the PC group; however, the total cells in the BALF of LGG treated groups
decreased. (B) The eosinophil is the hallmark of asthma. In the PC group the eosinophils significantly increased compared to LGG
treated groups. (C and D) The monocyte and lymphocyte cell counts. The statistical analysis compared OVA-treated mice and is
represented as: * p < 0.05, ** p < 0.01, and *** p < 0.001.
Figure 5. The effects of the Lactobacillus rhamnosus GG (LGG) treatment on Treg and Th1 cytokine levels [transforming growth
factor (TGF)-b, interferon (IFN)-g, and interleukin (IL)-12] in the ovalbumin (OVA)-treated mice in serum and bronchoalveolar
lavage fluid (BALF). Serum and BALF in Th1 and Treg cytokine concentrations were obtained from the normal control group and OVA
sensitized/challenged mice (positive control, PC) or in the presence of treatment with LGG. (AeC) the Th1 (IL-12, IFN- g) and Treg
(TGF-b) cytokines detected in serum and (DeF) the Th1 and Treg cytokines detected in BALF. In LGG-treated groups the Th1 cy-
tokines in the serum and BALF increased significantly compared with the PC group. In the oral LGG groups, however, the Treg
cytokines in serum and BALF decreased compared with PC group. The statistical analysis compared OVA-treated mice and is
represented as: * p < 0.05, ** p < 0.01, and *** p < 0.001.
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Figure 6. The effects of the Lactobacillus rhamnosus GG (LGG) treatment on Th2 cytokine levels [interleukin (IL)-4, IL-5, IL-10,
and IL-13] in the ovalbumin (OVA)-treated mice in serum and bronchoalveolar lavage fluid (BALF). Serum and BALF in Th2 cytokine
concentrations were obtained from the normal control group and OVA sensitized/challenged mice (positive control) or in the
presence of treatment with LGG. (AeD) The Th2 (IL-4, IL-5, and IL-13) cytokines detected in serum and (EeH) in BALF. In LGG-
treated groups the Th2 cytokines in serum and BALF were significantly decreased compared with positive control group. The
statistical analysis compared OVA-treated mice and is represented as: * p < 0.05, ** p < 0.01, and *** p < 0.001.
Oral LGG could decrease airway inflammation 631control group. After the LGG treatment, in both of the
groups treated with LGG in the allergic asthma models,
there was significantly less MMP9 expression. LGG treat-
ment therefore led to a significant decrease in MMP9
expression in serum and BALF.Figure 7. The effects of the Lactobacillus rhamnosus GG (LGG) tr
were obtained on Day 28 from (A) the normal control group and (B)
of, (C) pre-treatment with LGG, or (D) post LGG treatment, which
cation ratio of 1:200. The positive control group shows severe infl
significantly decreased airway inflammation compared with the poDiscussion
In this study, the allergen-induced airway inflammatory
mouse model was used to explain the role of OVA in
mediating pulmonary inflammation, promoting airwayeatment on allergen-induced airway inflammation. Lung tissues
the ovalbumin (OVA) sensitized/challenged mice in the absence
were stained with hematoxylin and eosin and with a magnifi-
ammation in the airway. However, the oral LGG groups show
sitive control group.
Table 1 The effects of the Lactobacillus rhamnosus GG (LGG) treatment on MMP9 expression in serum and bronchoalveolar
lavage fluid (BALF)a
Samples Group
Normal control
(n Z 5)
Positive control
(n Z 9)
Pre-LGG
(n Z 7)
Post-LGG
(n Z 5)
Serum (ng/mL) 0.0798  1.4** 4.37  3.31 2.34  1.79** 2.97  2.2**
BALF (ng/mL) 0.0973  2.01** 5.792  6.32 2.91  3.32** 3.06  1.42*
a Serum and BALF were obtained on Day 28 from the normal control group, the ovalbumin (OVA)-sensitization group and pre- or post-
treat LGG groups, which were detected with enzyme-linked immunosorbent assay. The positive control group had shown more MMP9
expression in serum and BALF. However, groups receiving oral LGG had significantly decreased MMP9 compared with the positive control
group. The statistical analyses are compared with OVA-treated mice and represented as: * p < 0.05, ** p < 0.01, and *** p < 0.001.
632 C.-T. Wu et al.remodeling, and promoting airway hyper-reactivity to
methacholine. The BALB/c mice were found to be suscep-
tible to the IgE-mediated allergic responses.33 In addition to
the responses of the OVA sensitized/challenged mice
following an increase in the serum IgE level, the eosinophils
displayed hyperplasia in the mouse asthma model. Previous
studies have shown that the oral administration of LGG
during allergen sensitization induces a Th1-predominant
allergen-specific immune response in food-allergic mice
and balances the Th1/Th2 immune response.17 Previous
studies have also reported that in some atopic children oral
probiotics increase Th1 cytokines and inhibit allergen-
induced IgE and Th2 cytokines.34,35 Similarly, our results
showed the Th1/Th2 immune response in the allergen ani-
mal model. Moreover, our study also showed that oral LGG
decreased AHR and inflammation cells in the pre- and post-
treatment LGG groups. These results support the theory
that LGG may be an effective anti-allergy therapy.
Lammers et al18 reported that several probiotic thera-
pies decrease IL-1b, IL-8, and IFN-g mucosal gene expres-
sion, whereas the proinflammatory cytokines TNF-a, IL-6,
IL-12, and regulatory cytokines IL-10 and TGF-b are not
altered. In recent studies,36e39 IFN-g, IL-12, and TGF-b
increased significantly after treatment with LGG. These
different results may be caused by different probiotic
treatments or different allergic diseases but the mecha-
nisms of probiotic therapy should become clearer in the
future. In other studies with an allergy mouse model,
however, oral administration of probiotics has been shown
to suppress OVA-specific IgE production, and inhibit subse-
quent allergic sensitization that is caused by inducing Treg-
associated TGF-b production.40 After oral probiotics, the
levels of IFN-g and IL-10 become significantly higher than
those in non-treated mice.41 Th2 cytokine-IL-4 is known to
directly promote the features of asthma, such as eosinophil
infiltration, goblet cell metaplasia, AHR, IgE production in
serum, mastocytosis, airway remodeling, and Th2 induc-
tion/maintenance.
Herein, our results showed that the OVA-sensitized mice
expressed higher levels of IL-4 in serum and BALF than the
naı¨ve mice, but the IL-4 levels decreased after treatment
with LGG. Furthermore, previous studies have shown that
IL-10 and TGF-b production are associated with T cell
tolerance and Tregs, which are induced by mucosal expo-
sure to antigens.42 However, IL-10 was initially described as
a Th2 type cytokine, but further evidence suggests thatIL-10 is not specific to Th2 cells or Treg cells but instead is a
much more broadly expressed cytokine. IL-10 is expressed
by many cells including Th1, Th2, and Th17 cell subsets,
Treg cells, CD8þ T cells, and B cells.43 Other studies have
shown that IL-10 cannot only downregulate production of
IL-4 and IL-5 but can also stimulate B cell differentiation
and immunoglobulin secretion.44,45
Makela et al46 reported that OVA-sensitized and chal-
lenged IL-10/ mice develop a pulmonary response but
fail to exhibit AHR. Reconstitution of these deficient mice
with the IL-10 gene fully restores development of AHR to a
level comparable to control mice. Some studies, however,
have shown that in atopic children oral LGG results in
elevated IL-10 concentrations, indicating that specific
probiotics may have anti-inflammatory effects in vivo and
may also enhance regulatory or tolerance-inducing
mechanisms.34,47
Probiotics can increase Th1 cytokines and inhibit IgE and
Th2 cytokines. Conversely, in allergens produced by house
dust mites, oral probiotics reduce IL-10 responsiveness.48
Our study showed that after treatment with LGG, IL-10
levels in serum and BALF were significantly decreased
compared to OVA-sensitized mice. Previous study with LGG,
such as that by Szajewska et al,49 have demonstrated that
LGG is successful in decreasing the duration of acute diar-
rhea in children aged 1e36 months, and LGG is more effi-
cient in reducing diarrhea caused by rotavirus.
Previous studies have shown that MMP9 may play a role
in airway inflammation and remodeling in asthma; more-
over MMP9 concentrations increase in severe, persistent
asthma and following allergen challenge.50 Ohno et al51
stated that MMP9 is highly expressed in bronchial biopsies
or BALF from asthma patients, and MMP9 activity increases
after allergen challenge.52 In order to determine whether
MMP9 activity increases after an allergen challenge such as
OVA and to carry out further study of chronic asthma, we
examined MMP9 in this study. The MMP9 levels not only
increased in serum but also in BALF after OVA challenge;
these results are similar to those of previous studies.50e52
More importantly, in our study orally-administrated LGG
decreased MMP9 levels in BALF and serum.
In a probiotic study of a clinical trial with infants at high
risk for allergies, mothers received a probiotic mixture
(Bifidobacterium spp. and Propionibacteria spp.) or pla-
cebo during the past few months of pregnancy, and their
infants received the same mixture from birth until 6 months
Oral LGG could decrease airway inflammation 633of age. According to the study, no preventive effect of
asthma was observed until up to 5 years of age in those who
received the probiotic.53 Rosenfeldt et al54 in another
allergic study, demonstrated that oral intake of L. rham-
nosus and Lactobacillus reuteri improves clinical symptoms
in patients with atopic dermatitis. In addition to these re-
sults, a large cohort study of LGG administration for 4
weeks revealed decreased SCORing Atopic Dermatitis re-
sults in pediatric patients with atopic dermatitis.55 Many
animal studies have used various strains of probiotics in
animal models of asthma. Oral administration of probiotics
attenuates the symptoms of allergic asthma in a mouse
model and induces immune regulation by a CD4(þ)CD25(þ)
Foxp3(þ)Treg cellmediated mechanism.56,57 Similar to our
results, Yu et al58 reported that oral Lactobacillus casei
rhamnosus Lcr35 attenuates airway inflammation and AHR
in a mouse model of allergic airway inflammation.
In a previous study of the probiotic LGG, oral LGG
administration particularly suppressed allergen-induced
proliferative responses.59 Moreover, previous clinical
studies have suggested that probiotic microorganisms sup-
press Th2-type effector mechanisms.60 Our study had
similar results. Another study, however, showed that with
recurrent wheezing and an atopic family history, oral LGG
has no clinical effect on atopic dermatitis or asthma-
related events.61 It may be helpful to investigate molecu-
lar pathways after probiotic treatment in order to under-
stand the different study results. Another study reported
that there are insufficient current data to support the use
of probiotics for the treatment of established allergic dis-
eases.61 We have therefore designed definitive intervention
studies of LGG combined therapy in allergic diseases for
treatment and prevention. The results demonstrated that
oral LGG may inhibit and prevent airway inflammation, Th2
cytokine production, MMP9, etc. However, the mechanism
of oral LGG in inflammation remains unclear, so further
studies are needed.
Asthma is a complicated disease that requires further
investigation. This study found that oral LGG can inhibit
OVA-induced airway inflammation. Nevertheless, some
studies have reported that oral probiotics have little or no
clinical effect on allergic diseases. Our results suggested
that oral probiotics might be an additional or supplemen-
tary therapy to other clinical allergy therapies.Conflicts of interest
This study was supported by research grant from Chung
Shan Medical University Hospital (CSH-2013-C-003), Tai-
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